PPIDT00406
Drug Information
| Name | Mirikizumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG |
| DrugBank_ID | DB14910 |
| Type | biotech |
| Indication | Mirikizumab is indicated for the treatment of adult patients with moderate-to-severely active ulcerative colitis.[L48646,L48656,L48661] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
20 mg/1mL
|
| Injection, solution | Subcutaneous |
100 mg/1mL
|
| Injection, solution | Subcutaneous |
100 mg
|
| Injection, solution, concentrate | Intravenous |
300 mg
|
| Solution | Intravenous |
20 mg / mL
|
| Solution | Subcutaneous |
100 mg / mL
|